Radiopharmaceuticals and Lung Cancer

Mar 06, 2024
Episode
209
Share

This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discussion with three respected international clinicians about how these therapies play a role in both diagnostics and therapeutics and how they may soon be expanding.

Guest
Stephen Liu
Stephen Liu

MD

Chief of Hematology & Oncology, Head of Developmental Therapeutics, Associate Professor of Medicine
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Dr. Aman Chauhan
Aman Chauhan

MD

Assistant Professor of Medicine, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theranostic Program
University of Miami
Dr. Jaydira Del Rivero
Jaydira Del Rivero

MD

Associate Research Physician and Physician Scientist in the Developmental Therapeutics Branch
Director of the Neuroendocrine Tumor Program
National Cancer Institute
Dr. Ken Herrman
Ken Herrmann

MD

Chair of the Department of Nuclear Medicine
Universitatsmedizin Essen in Germany
Past Chair of the European Association of Nuclear Medicine Oncology & Theranostics Committee

Other Podcast